Mustang Competitors
| MBIO Stock | USD 0.78 0.12 13.33% |
Mustang Bio vs Traws Pharma Correlation
Very weak diversification
The correlation between Mustang Bio and TRAW is 0.44 (i.e., Very weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Mustang Bio and TRAW in the same portfolio, assuming nothing else is changed.
Moving together with Mustang Stock
Moving against Mustang Stock
| 0.73 | IMMP | Immutep Ltd ADR | PairCorr |
| 0.69 | DSGN | Design Therapeutics | PairCorr |
| 0.68 | ENGN | enGene Holdings Common | PairCorr |
| 0.6 | KYTX | Kyverna Therapeutics | PairCorr |
| 0.42 | 63E | ONWARD MEDICAL BV | PairCorr |
Mustang Bio Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Mustang Bio and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Mustang and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Mustang Bio does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Mustang Stock performing well and Mustang Bio Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Mustang Bio's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | 5.28 | 1.17 | 0.20 | 5.02 | 5.12 | 12.79 | 28.69 | |||
| BOLT | 3.12 | 0.06 | 0.01 | 0.18 | 3.85 | 8.22 | 18.19 | |||
| RNAZ | 4.22 | (0.42) | 0.00 | (0.24) | 0.00 | 8.35 | 34.47 | |||
| LYRA | 5.54 | (1.23) | 0.00 | (1.31) | 0.00 | 13.48 | 66.89 | |||
| ACXP | 4.46 | (1.24) | 0.00 | (0.61) | 0.00 | 10.84 | 49.19 | |||
| EVGN | 2.55 | (0.31) | 0.00 | (0.24) | 0.00 | 3.77 | 21.74 | |||
| DWTX | 4.73 | (0.92) | 0.00 | (0.67) | 0.00 | 7.78 | 33.43 | |||
| ABP | 4.74 | (1.60) | 0.00 | (0.97) | 0.00 | 10.52 | 36.77 | |||
| IMRN | 4.27 | (1.13) | 0.00 | 1.27 | 0.00 | 5.88 | 36.62 | |||
| TRAW | 6.95 | 0.04 | 0.00 | (0.30) | 8.74 | 17.70 | 58.96 |
Cross Equities Net Income Analysis
Compare Mustang Bio and related stocks such as Marker Therapeutics, Bolt Biotherapeutics, and Transcode Therapeutics Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MRKR | (1.1 M) | (2 M) | (5.9 M) | (5.5 M) | (30.9 M) | (34.1 M) | (2.5 M) | (11 M) | (148 M) | (21.4 M) | (28.7 M) | (41.9 M) | (29.9 M) | (8.2 M) | (10.7 M) | (9.7 M) | (10.1 M) |
| BOLT | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (30.5 M) | (60.7 M) | (98.6 M) | (88.1 M) | (69.2 M) | (63.1 M) | (56.8 M) | (59.6 M) |
| RNAZ | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (453.4 K) | (607.2 K) | (2.3 M) | (6.8 M) | (17.6 M) | (18.5 M) | (16.8 M) | (15.1 M) | (14.3 M) |
| LYRA | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (6 M) | (16.3 M) | (22.1 M) | (42.4 M) | (55.3 M) | (62.7 M) | (93.4 M) | (84.1 M) | (79.9 M) |
| ACXP | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (4.6 M) | (12.7 M) | (12.1 M) | (14.6 M) | (14.1 M) | (12.7 M) | (13.3 M) |
| EVGN | 645 K | 645 K | (2.5 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (18.1 M) | (23.4 M) | (27.8 M) | (26.6 M) | (23.9 M) | (16.5 M) | (14.8 M) | (15.6 M) |
| DWTX | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.5 M) | (10.3 M) | (16 M) | (12.2 M) | (5.3 M) | (12.3 M) | (11.1 M) | (11.7 M) |
| ABP | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (12.4 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (17.2 M) | (11.7 M) | (7.2 M) | (6.5 M) | (6.8 M) |
| IMRN | (1.6 M) | (2.3 M) | (3.5 M) | (2.7 M) | (2.7 M) | (7.1 M) | (6.8 M) | (3 M) | (4.7 M) | (2.9 M) | (8.4 M) | (2.9 M) | (3.8 M) | (6.9 M) | (5.2 M) | (4.7 M) | (4.9 M) |
| TRAW | (30.3 M) | (30.3 M) | (33.9 M) | (64.9 M) | (63.7 M) | (24 M) | (19.7 M) | (24.1 M) | (20.6 M) | (21.5 M) | (25.2 M) | (16.2 M) | (19 M) | (18.9 M) | (54.7 M) | (62.9 M) | (66 M) |
Mustang Bio and related stocks such as Marker Therapeutics, Bolt Biotherapeutics, and Transcode Therapeutics Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Mustang Bio financial statement analysis. It represents the amount of money remaining after all of Mustang Bio operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Mustang Bio Competitive Analysis
The better you understand Mustang Bio competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Mustang Bio's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Mustang Bio's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Mustang Bio Competition Performance Charts
Five steps to successful analysis of Mustang Bio Competition
Mustang Bio's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Mustang Bio in relation to its competition. Mustang Bio's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Mustang Bio in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Mustang Bio's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Mustang Bio, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Mustang Bio position
In addition to having Mustang Bio in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Macroaxis Index Thematic Idea Now
Macroaxis Index
An experimental equal-weighted index theme of selected equities generated based on Macroaxis rating and scoring system. The Macroaxis Index theme has 52 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Macroaxis Index Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Mustang Bio Correlation with its peers. To learn how to invest in Mustang Stock, please use our How to Invest in Mustang Bio guide.You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Will Biotechnology sector continue expanding? Could Mustang diversify its offerings? Factors like these will boost the valuation of Mustang Bio. Expected growth trajectory for Mustang significantly influences the price investors are willing to assign. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Mustang Bio data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Mustang Bio's market price often diverges from its book value, the accounting figure shown on Mustang's balance sheet. Smart investors calculate Mustang Bio's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Since Mustang Bio's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
Understanding that Mustang Bio's value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Mustang Bio represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. However, Mustang Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.